0      0

AM23-MN-32-O - AM23-MN-32-O: Moving Beyond the Label - How the MPHO Unique Identifier Improves Traceability and Enhances Biovigilance (Enduring)

‐ Oct 18, 2023 7:00pm

Credits: None available.

Although ISBT128 has been widely adopted for blood and cellular therapy, challenges persist in uniquely identifying biologic products during their lifecycle.The unique ID of a Medical Product of Human Origin (MPHO) has previously relied upon combining multiple elements. The lack of standardization of this information within electronic health records (EHRs) or electronic messaging interfaces makes it difficult to maintain product history.The MPHO Unique Identifier provides a harmonized way to capture key traceability data elements in a single unique identifier for data transfer and storage. This ID defines a standardized format that incorporates data fields already present on MPHO labels, including Processing Facility Identification Number, Product Description Code, Donation Identification Number, and Division Identifier, allowing ease in querying.This session will discuss the MPHO Unique Identifier and its successful use in Cellular Therapy, a first for the field.

Learning Objectives:

  • Define the purpose of the MPHO Unique Identifier and develop an understanding of how it is constructed from elements on the ISBT 128 label.
  • Describe how implementation of the MPHO Unique identifier can improve traceability and enhance biovigilance.
  • Explain how the MPHO Unique Identifier can be used in the electronic health record and in electronic messaging and how it enables biologic product/cellular therapy product use in the production environment.
  • Describe options available for the electronic exchange of information about medical products of human origin.




  • Geoffrey Browne:
    STEMSOFT: Full-time/Part-time Employee or Owner (Ongoing)
  • Karen Moniz, MHA, MT(ASCP)SBB:
    No financial relationships to disclose
  • Mandy O'Leary, MD, MPH:
    No financial relationships to disclose


Credits: None available.